SGLT1/SGLT2抑制剂在预防和治疗心力衰竭方面的价值判断
Value Judgment of SGLT1/SGLT2 Inhibitors in the Prevention and Treatment of Heart Failure
DOI: 10.12677/ACM.2023.13122669, PDF,   
作者: 董兴梅*：承德医学院研究生学院，河北 承德；马利祥#, 汤秀英：秦皇岛市第一医院心血管内科，河北 秦皇岛
关键词: 钠–葡萄糖转运体1抑制剂；钠–葡萄糖转运体2抑制剂；心力衰竭；Sodium-Glucose Transporter 1 Inhibitor； Sodium-Glucose Transporter 2 Inhibitor； Heart Failure
摘要: 心力衰竭是一种心脏疾病终末期表现出来的综合征，由于人口老龄化，心力衰竭患病率正在增加，估计占全球人口的1%至2%。此外，心力衰竭导致高死亡率和发病率，患者的生活质量通常较差。钠–葡萄糖转运体2抑制剂(SGLT2i)是一种新型的降糖药，然而目前已成为治疗心力衰竭的新兴药物，但其作用机制尚不清楚。越来越多关于SGLT2i的研究发现这些药可以诱导心脏代谢的变化而改善心功能，同时发现正常人或心血管病患者的心肌细胞表达SGLT1，却未见SGLT2表达。研究发现钠–葡萄糖转运体2 (SGLT2)抑制剂可以抑制钠–葡萄糖转运体1 (SGLT1)，从而可能对心血管系统产生有益影响。本文就SGLT1/SGLT2抑制剂在预防和治疗心力衰竭方面的价值判断作一综述。
Abstract: Heart failure is a syndrome that manifests in the end stage of heart disease. Due to population age-ing, the prevalence of heart failure is increasing and is estimated to account for 1% to 2% of the global population. In addition, heart failure leads to high mortality and morbidity, and patients of-ten have poor quality of life. Sodium-glucose transporter 2 inhibitor (SGLT2i) is a new type of hypo-glycemic drug, but it has become an emerging drug for the treatment of heart failure, but its mech-anism of action is still unclear. More and more studies on SGLT2i have found that these drugs can induce changes in cardiac metabolism and improve cardiac function. At the same time, it has been found that SGLT1 is expressed in cardiomyocytes of normal people or patients with cardiovascular disease, but SGLT2 is not expressed. Sodium-glucose transporter 2 (SGLT2) inhibitors have been found to inhibit sodium-glucose transporter 1 (SGLT1), which may have beneficial cardiovascular effects. This article reviews the value judgment of SGLT1/SGLT2 inhibitors in the prevention and treatment of heart failure.
文章引用：董兴梅, 马利祥, 汤秀英. SGLT1/SGLT2抑制剂在预防和治疗心力衰竭方面的价值判断[J]. 临床医学进展, 2023, 13(12): 18976-18981. https://doi.org/10.12677/ACM.2023.13122669

参考文献

[1] Herrington, W.G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L.H., et al. (2021) Cardiac, Renal, and Meta-bolic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: A Position Paper from the European Society of Cardiology Ad-Hoc Task Force on Sodium-Glucose Co-Transporter 2 Inhibitors. European Journal of Heart Failure, 23, 1260-1275. [Google Scholar] [CrossRef] [PubMed]
[2] McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. [Google Scholar] [CrossRef] [PubMed]
[3] Cinti, F., Moffa, S., Impronta, F., Cefalo, C.M., Sun, V.A., Sorice, G.P., Mezza, T. and Giaccari, A. (2017) Spotlight on Ertugliflozin and Its Potential in the Treatment of Type 2 Diabetes: Evidence to Date. Drug Design, Development and Therapy, 11, 2905-2919. [Google Scholar] [CrossRef] 
[4] Pitt, B., Bhatt, D.L. and Metra, M. (2022) Does SGLT1 Inhibition Add to the Benefits of SGLT2 Inhibition in the Prevention and Treatment of Heart Failure? European Heart Journal, 43, 4754-4757. [Google Scholar] [CrossRef] [PubMed]
[5] Uthman, L., Homayr, A., Juni, R.P., Spin, E.L., Kerindongo, R., Boomsma, M., et al. (2019) Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Cellular Physiology and Biochemistry, 53, 865-886. [Google Scholar] [CrossRef] [PubMed]
[6] Endemann, D.H. and Schiffrin, E.L. (2004) Endothelial Dysfunction. Journal of the American Society of Nephrology, 15, 1983-1992. [Google Scholar] [CrossRef] 
[7] Patel, A.R., Kuvin, J.T., Pandian, N.G., Smith, J.J., Udelson, J.E., Mendelsohn, M.E., Konstam, M.A. and Karas, R.H. (2001) Heart Failure Etiology Affects Peripheral Vascular Endothelial Function after Cardiac Transplantation. Journal of the American College of Cardiology, 37, 195-200. [Google Scholar] [CrossRef] 
[8] Gaspari, T., Spizzo, I., Liu, H., Hu, Y., Simpson, R.W., Widdop, R.E. and Dear, A.E. (2018) Dapagliflozin Attenuates Human Vascular Endothelial Cell Activation and Induces Vasorelaxation: A Potential Mechanism for Inhibition of Atherogenesis. Diabetes and Vascular Disease Research, 15, 64-73. [Google Scholar] [CrossRef] [PubMed]
[9] Mancini, S.J., Boyd, D., Katwan, O.J., Strembitska, A., Almabrouk, T.A., Kennedy, S., Palmer, T.M. and Salt, I.P. (2018) Canagliflozin Inhibits Interleukin-1β-Stimulated Cyto-kine and Chemokine Secretion in Vascular Endothelial Cells by AMP-Activated Protein Kinase-Dependent and -Independent Mechanisms. Scientific Reports, 8, Article No. 5276. [Google Scholar] [CrossRef] [PubMed]
[10] Juni, R.P., Kuster, D.W.D., Goebel, M., Helmes, M., Musters, R.J.P., van der Velden, J., Koolwijk, P., Paulus, W.J. and van Hinsbergh, V.W.M. (2019) Cardiac Microvascular Endo-thelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC: Basic to Translational Science, 4, 575-591. [Google Scholar] [CrossRef] [PubMed]
[11] Uthman, L., Nederlof, R., Eerbeek, O., Baartscheer, A., Schu-macher, C., Buchholtz, N., Hollmann, M.W., Coronel, R., Weber, N.C. and Zuurbier, C.J. (2019) Delayed Ischaemic Contracture Onset by Empagliflozin Associates with NHE1 Inhibition and Is Dependent on Insulin in Isolated Mouse Hearts. Cardiovascular Research, 115, 1533-1545. [Google Scholar] [CrossRef] [PubMed]
[12] Baker, H.E., Kiel, A.M., Luebbe, S.T., Simon, B.R., Earl, C.C., Regmi, A., Roell, W.C., Mather, K.J., Tune, J.D. and Goodwill, A.G. (2019) Inhibition of Sodium-Glucose Cotransporter-2 Pre-serves Cardiac Function during Regional Myocardial Ischemia Independent of Alterations in Myocardial Substrate Utili-zation. Basic Research in Cardiology, 114, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[13] Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Long, W., Soni, S., Byrne, N.J., Barr, A., et al. (2021) Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodi-um/Glucose Cotransporter 2 Inhibitor Empagliflozin. Circulation, 143, 2188-2204. [Google Scholar] [CrossRef] 
[14] Azam, M.A., Chakraborty, P., Si, D., Du, B., Massé, S., Lai, P.F.H., Ha, A.C.T. and Nanthakumar, K. (2021) Anti-Arrhythmic and Inotropic Effects of Empagliflozin Following Myocardial Ischemia. Life Sciences, 276, Article ID: 119440. [Google Scholar] [CrossRef] [PubMed]
[15] Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B. and List, J. (2013) Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 15, 853-862. [Google Scholar] [CrossRef] [PubMed]
[16] Connelly, K.A., Zhang, Y., Visram, A., Advani, A., Batchu, S.N., Desjardins, J.F., Thai, K. and Gilbert, R.E. (2019) Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure with Preserved Ejection Fraction. JACC: Basic to Translational Science, 4, 27-37. [Google Scholar] [CrossRef] [PubMed]
[17] Byrne, N.J., Parajuli, N., Levasseur, J.L., Boisvenue, J., Beker, D.L., Masson, G., Fedak, P.W.M., Verma, S. and Dyck, J.R.B. (2017) Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC: Basic to Translational Science, 2, 347-354. [Google Scholar] [CrossRef] [PubMed]
[18] Shi, L., Zhu, D., Wang, S., Jiang, A. and Li, F. (2019) Dapagli-flozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. American Journal of Hypertension, 32, 452-459. [Google Scholar] [CrossRef] [PubMed]
[19] Verma, S., Garg, A., Yan, A.T., Gupta, A.K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C.D. and Connelly, K.A. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care, 39, e212-e213. [Google Scholar] [CrossRef] [PubMed]
[20] Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgeri-nos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D.R. and Bekiari, E. (2021) Comparative Efficacy of Glucose-Lowering Medications on Body Weight and Blood Pressure in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes, Obesity and Metabolism, 23, 2116-2124. [Google Scholar] [CrossRef] [PubMed]
[21] McGuire, D.K., Shih, W.J., Cosentino, F., Charbonnel, B., Cherney, D.Z.I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., Gantz, I., Terra, S.G., Masiukiewicz, U. and Cannon, C.P. (2021) Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis. JAMA Cardiology, 6, 148-158. [Google Scholar] [CrossRef] [PubMed]
[22] Zheng, C., Lin, M., Chen, Y., Xu, H., Yan, L. and Dai, H. (2021) Effects of Sodium-Glucose Cotransporter Type 2 Inhibitors on Cardiovascular, Renal, and Safety Outcomes in Patients with Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Cardiovascular Diabetology, 20, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[23] Gilbert, R.E. and Connelly, K.A. (2019) Reduction in the Inci-dence of Myocardial Infarction with Sodium-Glucose Linked Cotransporter-2 Inhibitors: Evident and Plausible. Cardio-vascular Diabetology, 18, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[24] Wright, E.M., Loo, D.D. and Hirayama, B.A. (2011) Biology of Human Sodium Glucose Transporters. Physiological Reviews, 91, 733-794. [Google Scholar] [CrossRef] [PubMed]
[25] Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015) Proteomics. Tissue-Based Map of the Human Proteome. Science, 347, Article ID: 1260419. [Google Scholar] [CrossRef] [PubMed]
[26] Tsimihodimos, V., Filippas-Ntekouan, S. and Elisaf, M. (2018) SGLT1 Inhibition: Pros and Cons. European Journal of Pharmacology, 838, 153-156. [Google Scholar] [CrossRef] [PubMed]
[27] Bell, R.M. and Yellon, D.M. (2018) SGLT2 Inhibitors: Hypoth-eses on the Mechanism of Cardiovascular Protection. The Lancet Diabetes & Endocrinology, 6, 435-437. [Google Scholar] [CrossRef] 
[28] Kanwal, A., Nizami, H.L., Mallapudi, S., Putcha, U.K., Mo-han, G.K. and Banerjee, S.K. (2016) Inhibition of SGLT1 Abrogates Preconditioning-Induced Cardioprotection against Ischemia-Reperfusion Injury. Biochemical and Biophysical Research Communications, 472, 392-398. [Google Scholar] [CrossRef] [PubMed]
[29] Cefalo, C.M.A., Cinti, F., Moffa, S., Impronta, F., Sorice, G.P., Mezza, T., Pontecorvi, A. and Giaccari, A. (2019) Sotagliflozin, the First Dual SGLT Inhibitor: Current Outlook and Perspectives. Cardiovascular Diabetology, 18, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[30] Pitt, B. and Bhatt, D.L. (2021) Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes? Circulation, 144, 4-6. [Google Scholar] [CrossRef] 
[31] Pitt, B., Steg, G., Leiter, L.A. and Bhatt, D.L. (2022) The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial In-farction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 36, 561-567. [Google Scholar] [CrossRef] [PubMed]
[32] Lee, Y.T., Mohd Ismail, N.I. and Wei, L.K. (2021) Microbiome and Ischemic Stroke: A Systematic Review. PLOS ONE, 16, e0245038. [Google Scholar] [CrossRef] [PubMed]
[33] Lin, N., Lin, H., Yang, Q., Lu, W., Sun, Z., Sun, S., Meng, L., Chi, J. and Guo, H. (2021) SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy via the JNK and p38 Pathway. Frontiers in Pharmacology, 11, Article ID: 598353. [Google Scholar] [CrossRef] [PubMed]
[34] Li, Z., Agrawal, V., Ramratnam, M., Sharma, R.K., D’Auria, S., Sincoular, A., Jakubiak, M., Music, M.L., Kutschke, W.J., Huang, X.N., Gifford, L. and Ahmad, F. (2019) Cardiac Sodium-Dependent Glucose Cotransporter 1 Is a Novel Media-tor of Ischaemia/Reperfusion Injury. Cardiovascular Research, 115, 1646-1658. [Google Scholar] [CrossRef] [PubMed]
[35] Seidelmann, S.B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., et al. (2018) Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. Journal of the American College of Cardiology, 72, 1763-1773. [Google Scholar] [CrossRef] [PubMed]
[36] Bhatt, D.L., Szarek, M., Steg, P.G., Cannon, C.P., Leiter, L.A., McGuire, D.K., et al. (2021) Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New Eng-land Journal of Medicine, 384, 117-128. [Google Scholar] [CrossRef] 
[37] Bhatt, D.L., Szarek, M., Pitt, B., Cannon, C.P., Leiter, L.A., McGuire, D.K., et al. (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England Journal of Medicine, 384, 129-139. [Google Scholar] [CrossRef] 
[38] Ishida, N., Saito, M., Sato, S., Tezuka, Y., Sanbe, A., Taira, E. and Hirose, M. (2021) Mizagliflozin, a Selective SGLT1 Inhibitor, Improves Vascular Cognitive Impairment in a Mouse Model of Small Vessel Disease. Pharmacology Research & Perspectives, 9, e00869. [Google Scholar] [CrossRef] [PubMed]

为你推荐